← All trials
NCT05682482
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 7, 2022
- Primary completion
- May 31, 2026
- Completion date
- May 31, 2026
- First posted
- Jan 12, 2023
- Last posted
- Jun 12, 2023
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Erasmus University RotterdamLead sponsor
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
- Erasmus University RotterdamOverall official - principal investigator
- Erasmus University RotterdamSponsor investigator
- ACE Pharmaceuticals BVCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.